ESMO Breast 2021 | Racial diversity in FDA registration trials for breast cancer

Mark Lythgoe, MD, Imperial College London & Hammersmith Hospital, London, UK, talks on racial disparities in breast cancer, highlighting reporting on racial diversity in FDA registration trials. Dr Lythgoe comments on the need for better representation of black participants in registration trials, in particular in relation to triple-negative breast cancer (TNBC). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.